Thalassemia - Pipeline Review, H1 2016

Description: Thalassemia - Pipeline Review, H1 2016

Summary

‘Thalassemia - Pipeline Review, H1 2016’, provides an overview of the Thalassemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thalassemia
- The report reviews pipeline therapeutics for Thalassemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thalassemia therapeutics and enlists all their major and minor projects
- The report assesses Thalassemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thalassemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thalassemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thalassemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Thalassemia Overview
Therapeutics Development
Pipeline Products for Thalassemia - Overview
Pipeline Products for Thalassemia - Comparative Analysis
Thalassemia - Therapeutics under Development by Companies
Thalassemia - Therapeutics under Investigation by Universities/Institutes
Thalassemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thalassemia - Products under Development by Companies
Thalassemia - Products under Investigation by Universities/Institutes
Thalassemia - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Acino Pharma AG
Agios Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
Bluebird bio, Inc.
Editas Medicine, Inc.
Emmaus Medical, Inc.
Errant Gene Therapeutics, LLC
Gamida Cell Ltd.
Incyte Corporation
Ionis Pharmaceuticals, Inc.
IRBM Science Park SpA
Johnson & Johnson
Kiadis Pharma B.V.
La Jolla Pharmaceutical Company
Merck & Co., Inc.
PharmaEssentia Corporation
Protagonist Therapeutics Inc.
Sangamo BioSciences, Inc.
Thalassemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACY-957 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AG-348 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-TMP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATIR-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BB-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BPX-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BtX-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNTO-530 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CordIn - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Thalassemia and Hemochromatosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress

glutamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress

GSK-2696277 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

ISIS-TMPRSS6LRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress

LJPC-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

luspatercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress

M-012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

NiCord - Drug Profile
Product Description
Mechanism of Action
R&D Progress

PB-04 - Drug Profile
Product Description
Mechanism of Action

R&D Progress

Peptide Agonists of Hepcidin for Beta-Thalassemia and Juvenile Hemochromatosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SCD-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Beta Thalassemia and Sickle Cell Anemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Histone Deacetylase 1 for Beta-Thalassemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sotatercept - Drug Profile

Product Description
Hematology Association

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Thalassemia, H1 2016
Number of Products under Development for Thalassemia - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2016
Thalassemia - Pipeline by Acceleron Pharma, Inc., H1 2016
Thalassemia - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
Thalassemia - Pipeline by Acino Pharma AG, H1 2016
Thalassemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2016
Thalassemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
Thalassemia - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
Thalassemia - Pipeline by Bluebird bio, Inc., H1 2016
Thalassemia - Pipeline by Editas Medicine, Inc., H1 2016
Thalassemia - Pipeline by Emmaus Medical, Inc., H1 2016
Thalassemia - Pipeline by Errant Gene Therapeutics, LLC, H1 2016
Thalassemia - Pipeline by Gamida Cell Ltd., H1 2016
Thalassemia - Pipeline by Incyte Corporation, H1 2016
Thalassemia - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
Thalassemia - Pipeline by IRBM Science Park SpA, H1 2016
Thalassemia - Pipeline by Johnson & Johnson, H1 2016
Thalassemia - Pipeline by Kiadis Pharma B.V., H1 2016
Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H1 2016
Thalassemia - Pipeline by Merck & Co., Inc., H1 2016
Thalassemia - Pipeline by PharmaEssentia Corporation, H1 2016
Thalassemia - Pipeline by Protagonist Therapeutics Inc., H1 2016
Thalassemia - Pipeline by Sangamo BioSciences, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Thalassemia Therapeutics - Recent Pipeline Updates, H1 2016
Thalassemia - Dormant Projects, H1 2016
List of Figures
Number of Products under Development for Thalassemia, H1 2016
Number of Products under Development for Thalassemia - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3674263/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Thalassemia - Pipeline Review, H1 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3674263/">http://www.researchandmarkets.com/reports/3674263/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCH3X2KI</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Electronic (PDF) - Single User:</th>
<th>USD 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World